Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03977090 |
Title庚妥尼单抗（GB226）联合福喹替尼治疗转移性结直肠癌 | 阶段
第 1 阶段
|
Date Added 2019-06-06 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, Geptanolimab Injection, Elunate |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05319314 |
TitleGCC19CART for Patients With Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2022-04-08 |
地点
California, United States
Colorado, United States Massachusetts, United States Michigan, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
GCC19CART |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04866862 |
TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-04-30 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Combination of Fruquintinib and Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05627635 |
TitleFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-11-25 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab, fluorouracil, Leucovorin Calcium, oxaliplatin |
标签
MSS/ MMRp
|
| NCT ID NCT06801665 |
TitleFMT+ QL1706+bevacizumab+ XELOX As First-line Treatment for Advanced MSS-type Colon Cancer with Liver Metastasis | 阶段
第二阶段
|
Date Added 2025-01-30 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT05277051 |
Title对晚期实体瘤患者进行的 GSK4381562 首次人体研究 | 阶段
第 1 阶段
|
Date Added 2022-03-14 |
地点
California, United States
North Carolina, United States Oklahoma, United States Pennsylvania, United States Texas, United States Utah, United States 澳大利亚 加拿大 中国 法国 日本 大韩民国 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Dostarlimab, GSK4381562 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03860272 |
TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer | 阶段
第 1 阶段
|
Date Added 2019-03-01 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05409417 |
TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status | 阶段
第二阶段
|
Date Added 2022-06-08 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物
Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX |
标签
MSS/ MMRp
|
| NCT ID NCT03795311 |
Title评估 FOLFIRINOX3 贝伐单抗治疗结直肠癌患者的疗效和安全性（FOLFIRINOX 3） | 阶段
Phase 1, Phase 2
|
Date Added 2019-01-07 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
FOLFIRINOX 贝伐单抗 |
标签
MSS/ MMRp
|
| NCT ID NCT04895722 |
TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | 阶段
第二阶段
|
Date Added 2021-05-20 |
地点
Florida, United States
Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States 比利时 加拿大 Colombia Costa Rica 丹麦 Estonia 法国 德国 希腊 Guatemala Hungary 意大利 大韩民国 Lithuania 荷兰 波兰 Romania Russian Federation 西班牙 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda |
标签
MSI-H/ MMRd
|
